- Home
- FFC vs SLN Comparison
FFC vs SLN Comparison
Compare FFC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- SLN
- Stock Information
- Founded
- FFC 1983
- SLN 1994
- Country
- FFC United States
- SLN United Kingdom
- Employees
- FFC N/A
- SLN N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- SLN Health Care
- Exchange
- FFC Nasdaq
- SLN Nasdaq
- Market Cap
- FFC 781.4M
- SLN 842.4M
- IPO Year
- FFC N/A
- SLN N/A
- Fundamental
- Price
- FFC $15.56
- SLN $7.22
- Analyst Decision
- FFC
- SLN Strong Buy
- Analyst Count
- FFC 0
- SLN 4
- Target Price
- FFC N/A
- SLN $61.50
- AVG Volume (30 Days)
- FFC 164.1K
- SLN 529.5K
- Earning Date
- FFC 01-01-0001
- SLN 11-14-2024
- Dividend Yield
- FFC 6.79%
- SLN N/A
- EPS Growth
- FFC N/A
- SLN N/A
- EPS
- FFC N/A
- SLN N/A
- Revenue
- FFC N/A
- SLN $21,773,221.00
- Revenue This Year
- FFC N/A
- SLN N/A
- Revenue Next Year
- FFC N/A
- SLN $104.98
- P/E Ratio
- FFC N/A
- SLN N/A
- Revenue Growth
- FFC N/A
- SLN N/A
- 52 Week Low
- FFC $11.90
- SLN $5.81
- 52 Week High
- FFC $14.96
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- FFC 32.33
- SLN 7.70
- Support Level
- FFC $15.57
- SLN $5.81
- Resistance Level
- FFC $15.92
- SLN $18.24
- Average True Range (ATR)
- FFC 0.19
- SLN 1.35
- MACD
- FFC -0.03
- SLN -1.15
- Stochastic Oscillator
- FFC 1.82
- SLN 7.94
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.